A U.S. appeals court, in a 2-1 ruling, said Teva’s product label for a copycat version of the heart drug Coreg encouraged doctors to prescribe the generic for an unapproved use. The majority called it a “narrow, case-specific review” that won’t affect other cases involving so-called skinny labels, though the third judge said it involved “sometimes labored, sometimes opaque” reasoning that could ...
Glaxo’s Win in Case Against Teva Lifts Other Drugmakers (2)
Aug. 5, 2021, 4:42 PM